Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression

This study has been completed.
Cascadian Therapeutics Inc.
Information provided by (Responsible Party):
Canadian Cancer Trials Group ( NCIC Clinical Trials Group ) Identifier:
First received: December 9, 2010
Last updated: April 10, 2015
Last verified: February 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2015
  Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)